The Durham, North Carolina-based startup's platform uses an image-based, tissue box-sized tool that cultures cells to capture long-term phenotypic behavior.
The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.
Namocell has partnered with the two firms to distribute its cell dispensing tool in South Korea, the Netherlands, Belgium, and Luxembourg.
The firm will use the proceeds to accelerate commercialization and deployment of its microfluidic technology and for working capital purposes.
The firm will use the net proceeds to advance commercialization of its microfluidic technology and for general corporate purposes.
Tomy Digital Biology has agreed to distribute Namocell's microfluidic-based cell platforms in the Japanese market.
The funding totals up to $5.6 million over five years and will incorporate Talis' proprietary SlipChip technology.
The Alameda, California-based startup will use the funding to advance the commercialization of its rapid diagnostic platform for infectious diseases.
The firm's microfluidic-based technology collects and purifies genetic material, causing a complete PCR reaction that identifies diseases in liquid samples.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.
Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.
A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.
In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.